Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Suraj Puthiyaveettil (Kozhikode, India), Suraj Puthiyaveettil, Jyothi Edakalavan. Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension. Eur Respir J 2016; 48: Suppl. 60, 1877

Member's Comments

No comment yet.

Related content which might interest you: Hemodynamic assessment of patients with pulmonary hypertension due to lung disease and/or hypoxia Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Endothelial dysfunction in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Immunity in idiopathic pulmonary arterial hypertension (IPAH), a role for activated DCs? Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006